Cencora, Inc 8-K, filed Sep 27, 2022
Cencora, Inc. (COR)
8-K
2022-09-27
For: 2022-09-22
View Original
Added on
April 10, 2026
About this 8-K
Cencora, Inc filed this 8-K on September 27, 2022, reporting on events of September 22, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________________________
FORM 8-K
_________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 22, 2022
_________________________________
(Exact name of registrant as specified in its charter)
_________________________________
Commission File Number: 1-16671
| (State or other jurisdiction of | (I.R.S. Employer | |||||||||||||
| incorporation or organization) | Identification No.) | |||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(610 ) 727-7000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | |||||||||
| (NYSE) | |||||||||||
_________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 22, 2022, the Board of Directors (the “Board”) of AmerisourceBergen Corporation (the “Company”) elected Lorence H. Kim, M.D., 48, to serve on the Board, effective October 1, 2022. Dr. Kim will also serve on the Board’s Finance Committee.
Dr. Kim has served as a Venture Partner of Third Rock Ventures, a venture capital firm, since September 2020. Prior to joining Third Rock Ventures, he served as Chief Financial Officer of Moderna, Inc. from April 2014 to June 2020 and as an advisor to Moderna through August 2020. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as Managing Director and Co-Head, Biotechnology Investment Banking. Dr. Kim has served as a director of Revolution Medicines, Inc. since July 2022, and has served as a director of Cowen Inc. since February 2022. Dr. Kim previously served on the board of directors of Seres Therapeutics, Inc. from October 2014 to June 2020. He also serves on the boards of directors of privately-held companies Flare Therapeutics Inc. and Abata Therapeutics, Inc., and on the Board of Governors of the American Red Cross and the Board of Trustees of Prep for Prep.
The Board determined that Dr. Kim is an independent director under the standards established by the New York Stock Exchange and the Board. Upon Dr. Kim’s election, the Board increased from ten to eleven members in accordance with the Company’s Bylaws.
As a non-employee director of the Company, Dr. Kim will be compensated for his service to the Company in accordance with the Company’s Compensation Policy for Non-Employee Directors, including an annual cash retainer of $100,000 and an annual equity award having a value of $200,000 on the date of grant.
There are no related party transactions between Dr. Kim and the Company that would require disclosure under Item 404(a) of Regulation S-K.
Item 7.01. Regulation FD Disclosure.
On September 27, 2022, the Company issued a news release announcing the election of Dr. Kim to the Board. A copy of the news release is attached hereto as Exhibit 99.1.
The information in this item, including Exhibit 99.1, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description of Exhibit | |||||||
99.1 | ||||||||
104 | Cover Page Interactive Data File (formatted as inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMERISOURCEBERGEN CORPORATION | |||||||||||
| Date: | September 27, 2022 | By: | /s/ Elizabeth S. Campbell | ||||||||
| Name: | Elizabeth S. Campbell | ||||||||||
| Title: | Executive Vice President & Chief Legal Officer | ||||||||||
| PRESS RELEASE | |||||
![]() | AmerisourceBergen Corporation | ||||
1 West First Avenue Conshohocken, PA 19428 | |||||
AMERISOURCEBERGEN ELECTS LORENCE H. KIM, M.D., TO ITS BOARD OF DIRECTORS
CONSHOHOCKEN, PA, September 27, 2022 — AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Lorence H. Kim, M.D., 48, as a new independent director, effective October 1, 2022. With the election of Dr. Kim, the Board of Directors will increase from ten to eleven members, nine of whom are independent.
“We look forward to Dr. Kim joining AmerisourceBergen’s Board of Directors. His business acumen, deep financial expertise, and healthcare knowledge will bring great perspective to the Board, AmerisourceBergen, and our stakeholders,” said Jane E. Henney, M.D., Lead Independent Director.
“Lorence’s background makes him an excellent fit for AmerisourceBergen as we advance our strategic growth priorities and vision,” said Steven H. Collis, Chairman, President & Chief Executive Officer. “Lorence’s sophistication and experience in pharmaceutical innovation will be incredibly valuable as we continue to focus on delivering long-term sustainable growth, guided by our purpose of being united in our responsibility to create healthier futures.”
Dr. Kim is currently a Venture Partner at Third Rock Ventures, LLC. From 2014 to 2020, he was the Chief Financial Officer of Moderna, Inc. Prior to that, he spent 14 years at Goldman, Sachs & Co., where his last role was Managing Director and Co-Head, Biotechnology Investment Banking. Dr. Kim is a director of Cowen Inc. and Revolution Medicines, Inc. He also serves as a director of Abata Therapeutics, Inc., and Flare Therapeutics Inc., and was a director at Seres Therapeutics, Inc., from 2014 to 2020. In addition, he is a member of the Board of Governors of the American Red Cross and a member of the Board of Trustees for Prep for Prep.
1
Dr. Kim earned his bachelor’s degree in Biochemical Sciences from Harvard University. He earned an M.B.A. in Health Care Management from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine.
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.
Contact: Bennett S. Murphy
Senior Vice President, Investor Relations
610-727-3693
bmurphy@amerisourcebergen.com
2
